American Cancer Society Recommends Regular PSA Blood Tests for Men Starting at 50

Landmark update moves from neutral advice to affirmative testing

November 12, 2026, 8:40 a.m. Eastern time.

In a major shift that could reshape routine healthcare for tens of millions of American men, the American Cancer Society issued updated national screening guidelines Thursday affirmatively recommending regular blood tests for prostate cancer starting at age 50 for men at average risk.

The revised recommendations, published in CA: A Cancer Journal for Clinicians, mark the organization’s first comprehensive overhaul of its prostate screening advice since 2010. For more than a decade, clinical guidance from most major health bodies urged a neutral stance termed “shared decision-making,” leaving the decision to undergo a prostate-specific antigen (PSA) blood test largely up to individual patient preference due to concerns over unnecessary biopsies and overtreatment.

However, cancer epidemiologists pointed to a troubling decade-long rise in late-stage, metastatic diagnoses across the United States as the driving force behind the new posture. Under the 2026 guidelines, clinicians are directed to actively recommend biennial PSA screening for average-risk men between the ages of 50 and 69, according to The Washington Post.

Earlier screening for Black men and high-risk families

The updated guidance establishes an even more aggressive schedule for populations facing disproportionate risks. Black men—who experience higher incidence rates and double the mortality risk from prostate cancer compared to white men—are advised to begin annual PSA screening starting at age 45.

The same age-45 threshold applies to men with a first-degree relative, such as a father or brother, diagnosed with prostate cancer before age 65. For individuals with multiple affected close relatives or known hereditary cancer syndromes such as BRCA1 or BRCA2 genetic mutations, screening discussions should begin as early as age 40, the society advised.

“Catching aggressive cancer before it breaches the prostate capsule remains the single greatest determinant of survival,” the authors wrote in the official guideline publication from the American Cancer Society. “Advances in risk stratification now enable us to recommend screening without subjecting large cohorts of men to harmful interventions.”

New prostate cancer guidelines from @AmericanCancer recommend regular PSA screening every 2 years for average-risk men ages 50-69, and yearly beginning at 45 for Black men and those with a family history.

— American Cancer Society (@AmericanCancer) November 12, 2026

Modern imaging and biomarkers to prevent overtreatment

Crucially, the society paired its recommendation for broader blood testing with strict new clinical pathways designed to prevent the overtreatment that led to skepticism over PSA testing in the 1990s and 2000s.

In earlier decades, an elevated PSA count often triggered an immediate, blind needle biopsy, frequently uncovering low-grade, slow-growing tumors that would never have threatened a patient’s life. The resulting surgeries and radiation therapies often left patients with permanent side effects, including incontinence and erectile dysfunction.

Under the 2026 protocol, an abnormal PSA reading must be confirmed with repeat blood draws, secondary biomarker blood or urine tests, and multiparametric MRI imaging before any biopsy is considered, as detailed by Urology Times. Furthermore, patients diagnosed with low-risk tumors are strongly directed toward active surveillance—regular monitoring rather than immediate surgery or radiation.

Timeline of U.S. prostate cancer screening standards

1994: The FDA approves the PSA blood test for cancer screening alongside digital exams; widespread testing begins nationwide.

2012: The U.S. Preventive Services Task Force (USPSTF) recommends against routine PSA screening, citing high rates of overdiagnosis and complications from overtreatment.

2018: Guidelines soften to recommend individualized "shared decision-making" for men ages 55 to 69, while metastatic diagnoses begin creeping upward.

November 12, 2026: The American Cancer Society formally publishes updated guidelines establishing routine biennial screening for men 50–69 and annual screening at 45 for high-risk groups.

Sources and visual credits

American Cancer Society: updated screening guidelines · The Washington Post: analysis of revised PSA recommendations · Urology Times: clinical impact on biopsies and imaging · American Cancer Society on X: guideline release announcement

Header and thumbnail visual: Newstro editorial newsroom section graphic.